// App-Quantinova.ai

: Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT).

Researchers

Presenter

  • Karim Fizazi

Principal Investigators

  • Namphuong Tran

  • Luis Enrique Fein

  • Nobuaki Matsubara

  • Alfredo Rodrguez Antoln

  • Mustafa Ozguroglu

  • Dingwei Ye

  • Susan Feyerabend

  • Andrew Protheroe

  • Giri Sulur

  • Yesenia Luna

  • Susan Li

  • Suneel Mundle

  • Kim N. Chi

Medical Centers

  • Department of Cancer Medicine, Institut Gustave Roussy, Paris-Sud University, Villejuif, France

  • Janssen Research & Development, Los Angeles, CA

  • Instituto de Oncologia de Rosario, Rosario, Argentina

  • Division of Breast and Medical Oncology, National Cancer Center Hospital East, Chiba, Japan

  • Hospital Universitario Doce de Octubre, Madrid, Spain

  • Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey

  • Fudan University Cancer Hospital, Shanghai, China

  • Studienpraxis Urologie, Nurtingen, Germany

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • Janssen Research and Development, LLC, Spring House, PA

  • Janssen Research & Development, LLC, Raritan, NJ

  • BC Cancer - Vancouver Centre, Vancouver, BC, Canada

Locations

  • France

  • United States

  • Argentina

  • Japan

  • Spain

  • Turkey

  • China

  • Germany

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

  • Prednisone

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • NCT01715285

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved